GB1033736A - Stable injectable protamine-active compositions - Google Patents

Stable injectable protamine-active compositions

Info

Publication number
GB1033736A
GB1033736A GB19703/62A GB1970362A GB1033736A GB 1033736 A GB1033736 A GB 1033736A GB 19703/62 A GB19703/62 A GB 19703/62A GB 1970362 A GB1970362 A GB 1970362A GB 1033736 A GB1033736 A GB 1033736A
Authority
GB
United Kingdom
Prior art keywords
protamine
formaldehyde
complex
sulphoxylate
bisulphite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB19703/62A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma Ltd
Original Assignee
Evans Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans Medical Ltd filed Critical Evans Medical Ltd
Priority to GB19703/62A priority Critical patent/GB1033736A/en
Priority to FR935613A priority patent/FR2614M/en
Publication of GB1033736A publication Critical patent/GB1033736A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Injectable compositions, for use in the combating of malignant tumours, comprise in dosage unit form in admixture with a parenterally acceptable pharmaceutical liquid carrier from 250 to 6000 mg. of protamine which may be in the form of the free base, a physiologically acceptable acid addition salt thereof or a protamine-active compound. The compositions can be stabilized by the inclusion of a formaldehyde-bisulphite or formaldehyde-sulphoxylate complex. Where such a complex is heated with protamine in aqueous alkaline solution, a protamine-active compound is formed. The bisulphite or sulphoxylate moiety of the formaldehyde complex is preferably in the form of an alkali metal salt, e.g. potassium or sodium salt. Suitable salts of protamine include the hydrochloride, hydrobromide, phosphate, nitrate, citrate, tartrate and sulphate. In examples, the protamine used is salmine (from salmon) and clupeine (from herring). The carrier is preferably sterile pyrogen-free water, optionally containing salts such as sodium chloride.
GB19703/62A 1962-05-22 1962-05-22 Stable injectable protamine-active compositions Expired GB1033736A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB19703/62A GB1033736A (en) 1962-05-22 1962-05-22 Stable injectable protamine-active compositions
FR935613A FR2614M (en) 1962-05-22 1963-05-21 Medicinal product for use against malignant tumors, based on protamine.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19703/62A GB1033736A (en) 1962-05-22 1962-05-22 Stable injectable protamine-active compositions

Publications (1)

Publication Number Publication Date
GB1033736A true GB1033736A (en) 1966-06-22

Family

ID=10133795

Family Applications (1)

Application Number Title Priority Date Filing Date
GB19703/62A Expired GB1033736A (en) 1962-05-22 1962-05-22 Stable injectable protamine-active compositions

Country Status (2)

Country Link
FR (1) FR2614M (en)
GB (1) GB1033736A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038500A2 (en) * 1998-01-30 1999-08-05 The Brigham And Women's Hospital, Inc. The human calcium-sensing receptor in the detection and treatment of cancer
EP2111871A1 (en) * 2008-04-26 2009-10-28 Sandoz AG Stabilised fluid formula
EP2113257A1 (en) * 2008-04-30 2009-11-04 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038500A2 (en) * 1998-01-30 1999-08-05 The Brigham And Women's Hospital, Inc. The human calcium-sensing receptor in the detection and treatment of cancer
WO1999038500A3 (en) * 1998-01-30 2000-04-13 Brigham & Womens Hospital The human calcium-sensing receptor in the detection and treatment of cancer
US6296833B1 (en) 1998-01-30 2001-10-02 The Brigham And Women's Hospital, Inc. Human calcium-sensing receptor in the detection and treatment of cancer
EP2111871A1 (en) * 2008-04-26 2009-10-28 Sandoz AG Stabilised fluid formula
WO2009130048A1 (en) * 2008-04-26 2009-10-29 Sandoz Ag Stabilized liquid formulation
EP2113257A1 (en) * 2008-04-30 2009-11-04 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer

Also Published As

Publication number Publication date
FR2614M (en) 1964-06-22

Similar Documents

Publication Publication Date Title
ES397611A1 (en) Zirconium rinse for phosphate coated metal surfaces
GB743726A (en) Improvements in and relating to the electrodeposition of nickel
GB1287673A (en) Injectable compositions
GB1038678A (en) Compounds having an adrenocorticotrophic hormone action and process for their manufacture
GB1033736A (en) Stable injectable protamine-active compositions
GB1323502A (en) Erythromycin derivatives
GB611483A (en) Improvements in the electrodeposition of nickel from aqueous acidic nickel baths
ES326448A1 (en) Procedure for obtaining a therapeutic composition of mucolitic action. (Machine-translation by Google Translate, not legally binding)
GB1387175A (en) Salts of iodomethanesulphonic acid
GB1107146A (en) Compositions and processes for electroless nickel plating
ES351689A1 (en) Improvements in or relating to Compositions Containing Choline Chloride
US2498200A (en) Stabilized thiamin
GB715976A (en) Improvements in medical preparations for removing toxic heavy metals from the human body
GB1145623A (en) Pharmaceutical composition
ES391536A1 (en) Procedure for obtaining antibacterial compositions. (Machine-translation by Google Translate, not legally binding)
GB1033378A (en) Stable injectable protamine-active solutions
ES312676A1 (en) Improvements introduced in the preparation of coated electrolytic baths for use in the production of nickel electrolytic deposits. (Machine-translation by Google Translate, not legally binding)
GB760567A (en) Improvements relating to chemical compositions particularly adapted for molluscacidal purposes
GB1287674A (en) Injectable compositions
GB967475A (en) Improvements in or relating to pharmaceutical compositions comprising a salt of (n-methylene-sulphoxylate)-4-amino-2-hydroxybenzoic acid
GB816592A (en) A method for the preparation of stable magnesium solutions of high concentration
GB894752A (en) Improvements in or relating to citric acid derivatives
DE3068259D1 (en) Directly injectable aqueous solutions of the alkali salts of canrenoic acid and of furosemide, and process for their production
GB621217A (en) Improvements in copper-tin alloy plating
GB535670A (en) Improved process for the treatment of tinplate and tinplate articles